^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPT-143

    i
    Other names: next-generation IL-2 conjugates, BPT-143
    Associations

    News

    Trials
    Company:
    Bright Peak Therap
    Drug class:
    T-cell stimulant, CD122 agonist
    Related drugs:
    Associations

    News

    Trials
    2years
    BPT-143: a fully synthetic alpha-dead IL-2 with a best-in-class preclinical pharmacodynamic and efficacy profile supporting first-in-human clinical development (AACR 2022)
    High-dose recombinant IL-2 (aldesleukin) is approved for treatment of advanced melanoma and renal cell carcinoma, however, major limitations restrict its therapeutic use. Both in vivo efficacy studies in murine tumor models as well as PD effects observed in NHP indicate that BPT-143 has a best-in-class profile among “not-alpha” IL-2 compounds currently in development. IND-enabling studies are ongoing and a first in human trial is planned to start in 2022.
    P1 data • PK/PD data • Preclinical
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    CD8 expression
    |
    Proleukin (aldesleukin) • BPT-143